ASP 1948
Alternative Names: ASP-1948; PTZ-329Latest Information Update: 28 May 2023
At a glance
- Originator Potenza Therapeutics
- Developer Astellas Pharma; Potenza Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 27 Apr 2023 Astellas Pharma in collaboration with Merck completes phase I trial in Solid tumours (Metastatic disease) in USA, United Kingdom, Taiwan, Portugal, Spain, South Korea, Canada, Japan, Italy (IV) (NCT03565445)
- 11 Feb 2022 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Japan (IV) (Astellas pipeline, February 2022)
- 11 Feb 2022 Discontinued - Phase-I for Solid tumours (Metastatic disease) in USA, United Kingdom, Taiwan, Portugal, Spain, South Korea, Canada, Japan, Italy (IV) (Astellas pipeline, February 2022)